If you're a KRAS nerd, get your holistic view of oncogenic KRAS signaling here: www.science.org/doi/10.1126/...
#KRAS #proteomics (4/4)

What makes it even better: All experiments were performed in a dose-resolved manner—so you can dive into dose-response curves in our interactive dashboards! #CurveCurator #BeautifulCurves (3/4)

We explore how inhibition of oncogenic KRAS signaling reshapes protein phosphorylation, ubiquitylation, and protein expression—across multiple time points, using various KRAS inhibitors, as well as upstream and downstream pathway inhibitors, in different KRAS-mutant cell lines. (2/4)

📢 Read the full paper here: doi.org/10.1038/s44320-025-00085-6 – we’d love to hear your thoughts! #CancerResearch #PDAC #MolecularBiology #Proteomics (4/4)

🔎 To uncover the molecular mechanisms driving this synergy, we employed both chemo- and phosphoproteomics (decryptM), which revealed how ATR inhibition disrupts the DNA damage response when combined with gemcitabine. (3/4)

🧫 Using large-scale phenotypic drug screening, we identified promising drug combinations that enhance tumor cell death - and found Gemcitabine and ATR inhibitors to synergize most effectively. (2/4)

We'll DM you

Our tool was built using Vue.js and D3.js and is free for public reuse (github.com/kusterlab/bi..., github.com/wilhelm-lab/...).
Thanks to everyone involved! 🥳 We're looking forward to seeing how it'll be received by the community. (6/6).

If canonical pathway diagrams are not enough for you, just build your own! PTMNavigator's editing mode allows you to design custom pathways, tailored to your data and research question. 🧑‍🔬 (5/6)